ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "corticosteroids"

  • Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium

    Achieving Medication-Free Remission in Juvenile Dermatomyositis

    Harneet Ghumman1, Ilaria Maccora2, Hermine Brunner1, Amy Cassedy3, Mekibib Altaye2, Asra Firdous1, Alexei Grom1, Daniel Lovell1, Angela Merritt1, Megan Quinlan-Waters1 and Sheila Angeles-Han2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
  • Abstract Number: 024 • 2023 Pediatric Rheumatology Symposium

    Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging

    Mark DiFrancesco, Ekemini Ogbu, Catherine Robben, Jennifer Huggins and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Prior research suggests that microvascular (MV) changes might be a biomarker for central nervous system (CNS) involvement of patients with systemic lupus erythematosus (SLE).…
  • Abstract Number: L17 • ACR Convergence 2022

    Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis

    Robert Maughan1, Andrew Porter1, Chanaka Dahanayake2, Claudia Ianonne1, Ritu Alapat1, Charis Pericleous1, Taryn Youngstein3 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Imperial NHS Trust, London, United Kingdom

    Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
  • Abstract Number: 0539 • ACR Convergence 2022

    Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use

    Anna Broder1, Wenzhu B. Mowrey2, Kazuki Yoshida3 and Karen Costenbader3, 1Hackensack University Medical Center, Hackensack, NJ, 2Albert Einstein College of Medicine, Bronx, NY, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
  • Abstract Number: 0590 • ACR Convergence 2022

    Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling

    Heather Faust1, Tan-Yun Cheng1, Ilya Korsunsky1, Gerald FM Watts1, David Moody1 and Michael Brenner2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The synovium encapsulates joints and contains fibroblasts which proliferate, become invasive, and drive disease progression in rheumatoid arthritis (RA) and osteoarthritis (OA). There is…
  • Abstract Number: 0621 • ACR Convergence 2022

    Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm

    Siska Wilantri1, Cindy Strehl1, Dimas Abdirama1, Timo Gaber1, Robert Biesen2 and Frank Buttgereit1, 1Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    Background/Purpose: Clinical symptoms of rheumatoid arthritis (RA), including pain, joint stiffness, and swelling, exhibit a distinct circadian rhythm that exacerbates in the early morning in…
  • Abstract Number: 0767 • ACR Convergence 2022

    Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies

    Megan Himmel, Alexandra Saltman and Brooke Pollock, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Cancer therapies that target immune checkpoints have gained a prominent role in the treatment of malignancy. These agents stimulate an impressive and sustained anti-tumour…
  • Abstract Number: 0866 • ACR Convergence 2022

    Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab

    Sheila Angeles-Han1, Grant Schulert1, Megan Quinlan-Waters1, Alexandra Duell1, Jennifer Huggins1, Tiffany Nguyen2, Cameron Sapp2, Sumit Sharma3, Sunil Srivastava4 and Arjun Sood2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Eye Institute, Cincinnati, OH, 3Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 4Cole Eye Institute, Cleveland Clinic, Cincinnati, OH

    Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
  • Abstract Number: 1106 • ACR Convergence 2022

    Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica on Glucocorticoid Therapy: A Randomized Clinical Trial

    Valerie Devauchelle1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, Christophe Richez4, Marie Truchetet5, Daniel Wendling6, ERIC TOUSSIROT7, aleth Perdriger8, jacques-eric gottenberg9, Renaud FELTEN10, Bruno Fautrel11, laurent chiche12, Pascal HILLIQUIN13, Catherine Le Henaff14, Benjamin Dervieux15, Guillaume Direz16, Isabelle Chary-Valckenaere17, Divi CORNEC18, Dewi Guellec19, Thierry MARHADOUR20, Emmanule Nowak19 and Alain Saraux21, 1Université de Bretagne Occidentale, Brest, France, 2CHRU de Tours, Tours, France, 3LE MANS general hospital, LE MANS, France, 4Université de Bordeaux, Bordeaux, France, 5Bordeaux University Hospital, Bordeaux, France, 6CHU, University Teaching Hospital, Besançon, France, 7CHU de Besançon, Besançon, France, 8Rennes University, Rennes, France, 9Strasbourg University Hospital, Strasbourg, France, 10Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 11Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, 12hopital europeen, Marseille, France, 13Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, 14Morlaix Hospital, Morlaix, France, 15Mulhouse Hospital, Mulhouse, France, 16Le Mans Hospital, Le Mans, France, 17Nancy University Hospital, Vandoeuvre, France, 18CHRU Brest, Brest, France, 19Brest University Hospital, Brest, France, 20CHU Cavale Blanche, Brest, France, 21CHU Brest, Brest, France

    Background/Purpose: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica (PMR). Interleukin-6 antagonists deserve evaluation in active glucocorticoid-dependent PMR. Our objective was to compare…
  • Abstract Number: 1549 • ACR Convergence 2022

    Toward Safer Glucocorticoid Therapy

    Xingyu Pan1, Qiongqiong Hou1, Jiahui Xu1, Yake Ma1, Jiawen Li1, Min Li1, Jing Su1, Xuerou Shi1, William Bracken2 and David Katz2, 1WuXi AppTec, Nantong, China, 2Sparrow Pharmaceuticals, Portland, OR

    Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
  • Abstract Number: 1584 • ACR Convergence 2022

    Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition Arthritis: A Multicenter Randomized Controlled Trial

    Tristan Pascart1, Pierre Robinet2, Sebastien Ottaviani3, Remi Leroy4, Nicolas Segaud5, Aurore Pacaud2, Hélène Luraschi2, Thibault Rabin2, Agathe Grandjean2, Xavier Deplanque6, Pierre Maciejasz6, Fabien Visade2, Alexandre Mackowiak2, Nicolas Baclet6, Antoine Lefebvre2, Jean-François Budzik2, Thomas Bardin7, Pascal Richette8, Laurène Norberciak2, Vincent Ducoulombier2 and Eric Houvenagel1, 1Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, 2Hôpital Saint-Philibert, Lomme, France, 3Hopital Bichat-Claude Bernard, Paris, France, 4Centre Hospitalier de Dunkerque, Dunkerque, France, 5Centre Hospitalier d'Armentières, Armentières, France, 6Hôpital Saint-Vincent-de-Paul, Lille, France, 7Hôpital Lariboisiere, Paris, France, 8Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Treatment of acute CPP arthritis mainly relies on expert opinion, as there are no trials that assessed the efficacy of anti-inflammatory drugs, despite the…
  • Abstract Number: 1795 • ACR Convergence 2022

    Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease

    Julien Damart1, Silvia Sirotti2, Mariano Andrès3, Edoardo Cipolletta4, Georgios Filippou5, Davide Carboni6, Emilio Filippucci7, Pilar Diez8, Abhishek Abhishek9, Augustin Latourte10, Hang-Korng Ea11, Sebastien Ottaviani12, Jean-Guillaume Letarouilly13, Renaud Desbarbieux14, Sahara Graf1, Laurène Norberciak1, Pascal Richette15 and Tristan Pascart16, 1Hôpital Saint-Philibert, Lomme, France, 2Università degli Studi di Milano, Milano, Italy, 3Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 4Polytechnic University of Marche, Ancona, Italy, 5Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, 6Luigi Sacco University, Milano, Italy, 7Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, 8Alicante University, Alicante, Spain, 9University of Nottingham, Nottingham, United Kingdom, 10Université de Paris, Paris, France, 11Lariboisière Hospital, Paris, France, 12Hopital Bichat-Claude Bernard, Paris, France, 13CHU Lille, Lille, France, 14Ch Boulogne-sur-Mer, Boulogne-sur-Mer, France, 15Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 16Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France

    Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease lacks recommendations on treatment strategies. This study reports on treatment modalities used in European tertiary hospitals for the management…
  • Abstract Number: 1837 • ACR Convergence 2022

    Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology

    Sonia Pastor Navarro1, Olga Compán Fernández1, Marta Ibáñez Martínez1, Belén Miguel Ibáñez1, Mireia Molina Pérez2, Ángel Beltrán Mazo2, Olga Martínez González1, Carlos Montilla Morales1, Ana Isabel Turrión Nieves1, Susana Gómez Castro3 and Cristina Hidalgo Calleja1, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 3Hospital Universitario Salamanca, Salamanca, Spain

    Background/Purpose: Ocular inflammatory involvement for being closely related to systemic autoimmune diseases is monitored and treated in our rheumatology visits. The most frequently studied by…
  • Abstract Number: 1843 • ACR Convergence 2022

    Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience

    Vivekanand Tiwari1, Vishnuteja Devalla2, Emily Campbell1 and William Rigby1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Essential Health St. Joseph's-Brainerd Clinic, Brainerd, MN

    Background/Purpose: Polymyalgia rheumatica (PMR) treatment is predominantly based on long-term corticosteroids, which results in significant corticosteroid-related toxicities. Studies1,2 have shown patients with PMR are exposed…
  • Abstract Number: 1909 • ACR Convergence 2022

    Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol

    Grégoire Cormier1, Amelie Denis2, CHARLES LESKE3, Stephane Varin1, Jerome Dimet4, Lucie Planche1 and Benoit Le Goff5, 1CHD Vendee, La Roche Sur Yon, France, 2CH Le Mans, Le Mans, France, 3Hospital, Cholet, France, 4CH Mont de Marsan, Mont de Marsan, France, 5CHU Nantes, Nantes, France

    Background/Purpose: Trapeziometacarpal osteoarthritis is highly prevalent (affects 10 to 25% of people). Treatment modalities consist of non-pharmacological and pharmacological measures, including either corticosteroid or hyaluronic…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences